CureDuchenne Cares is pleased to share important information about steroids use for Duchenne patients. Use of corticosteroids is part of the standards of care for Duchenne patients. Chronic use […]
CureDuchenne is pleased to share the following communication update from BioMarin to the Duchenne community regarding developments of their exon skipping program for exon 51. CureDuchenne has provided extensive support […]
CureDuchenne is pleased to share the following update to the Duchenne muscular dystrophy community from Lilly regarding the ongoing Phase 3 trial of tadalafil in boys with Duchenne. Eli Lilly […]
Today, CureDuchenne announced a $1 million investment in Capricor Therapeutics for a clinical trial to test its CDC (adult) stem cells as a cardiac therapy for Duchenne patients. CureDuchenne’s mission […]
Sarepta Therapeutics released the 168 week data for their exon skipping drug, eteplirsen, this morning. During a three year period, 7-13 year old boys with Duchenne (the age range of […]
Pfizer Inc. (NYSE:PFE) announced today enrollment of the first patient in a multicenter Phase II clinical trial of the investigational compound PF-06252616 in boys with Duchenne muscular dystrophy (DMD), a […]
Last weekend, I had the honor, along with Dr. Mike Kelly, CureDuchenne’s Chief Scientific Officer, and other TACT members, to review Duchenne research projects. CureDuchenne was able to look […]
Those who live with Duchenne muscular dystrophy have physical activity limitations that need to be addressed at school. It is important for those impacted with Duchenne to be included without further […]
Sarepta provided an 144 week update on eteplirsen at the World Muscle Society meeting. Here are some brief notes. Neutral charge as it passes through kidney; cleared through kidney […]
